Table 2.
Summary of mono and combined lipid-modifying therapies (LMT), overall and for the familial hypercholesterolaemia (FH) subgroup
| Treatmenta | No. of patients (%) | |
|---|---|---|
| Overall | FH | |
| Monotherapy | ||
| Statin | 954 (76.7%) | 234 (76.2%) |
| Other LMT | 10 (0.8%) | 1 (0.3%) |
| Ezetimibe | 7 (0.6%) | 2 (0.7%) |
| Combination therapy | ||
| Statin + ezetimibe | 132 (10.6%) | 50 (16.3%) |
| Statin + other LMT | 107 (8.6%) | 11 (3.6%) |
| Statins + other LMT + ezetimibe | 27 (2.2%) | 9 (2.9%) |
| Other LMT + ezetimibe | 7 (0.6%) | 0 (0%) |
| Total | 1244 (100%) | 307 (100%) |
aAnytime during the observation period. Each subject is included only once (e.g. if they received statin monotherapy for a portion of the observation period and statin + ezetimibe for another portion, they are included under statin + ezetimibe)